Indivior Pharmaceuticals, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Indivior Pharmaceuticals, Inc. (INDV) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of -$2.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-30.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-04-30
- Indivior Pharmaceuticals, Inc. unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2026-03-31 was -$2.00M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 3 month |
|---|---|
| 2026-03-31 | -$2.00M 10-Q · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |